Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Nehzat, Nasim; Mirmosayyeb, Omid; Barzegar, Mahdi; Vosoughi, Reza; Fazeli, Erfane; Shaygannejad, Vahid

Nehzat, Nasim; Mirmosayyeb, Omid; Barzegar, Mahdi; Vosoughi, Reza; Fazeli, Erfane; Shaygannejad, Vahid.

Afiliación

Nehzat N; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Mirmosayyeb O; Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
Barzegar M; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Vosoughi R; Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran.
Fazeli E; Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Shaygannejad V; Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Neurol Res Int ; 2021: 6679197, 2021.

Article en En | MEDLINE | ID: mdl-34336283

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies Idioma: En Revista: Neurol Res Int Año: 2021 Tipo del documento: Article País de afiliación: Irán

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google